Biotech Values

[DewDiligence]

To legitimately call that a "quad" agent, VKTX needs to co-formulate the DACRA with VK2735, which could be tricky from a business-risk standpoint. I.e., if there were a safety problem in a clinical trial of such a co-formulated agent, it might cause a setback to the VK2735 program even if the DACRA were solely responsible for the problem.